Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valganciclovir.

M Curran1, S Noble

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Oral valganciclovir offers an effective treatment for cytomegalovirus (CMV) retinitis in patients with AIDS, demonstrating comparable efficacy and tolerability to intravenous ganciclovir. This prodrug provides high bioavailability, simplifying CMV retinitis management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bovine congenital defects recorded by veterinary practitioners.

Reproduction in domestic animals = Zuchthygiene·2023
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

The effectiveness of exercise interventions to increase physical activity in Cystic Fibrosis: A systematic review.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2021
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Cytomegalovirus (CMV) retinitis is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
  • Ganciclovir has been a standard treatment, but requires intravenous administration.
  • Valganciclovir, an oral prodrug of ganciclovir, was developed to improve treatment convenience.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of oral valganciclovir compared to intravenous ganciclovir for CMV retinitis in AIDS patients.
  • To assess the pharmacokinetic profile of oral valganciclovir.

Main Methods:

  • A randomized, nonblind study comparing oral valganciclovir (900 mg BID then QD) with intravenous ganciclovir (5 mg/kg BID then QD).
  • Treatment duration for induction was 3 weeks, followed by maintenance therapy.

Related Experiment Videos

  • Efficacy was assessed by treatment response in newly diagnosed CMV retinitis.
  • Tolerability was monitored through adverse event reporting.

    • Main Results:

    • Oral valganciclovir demonstrated comparable efficacy to intravenous ganciclovir in treating newly diagnosed CMV retinitis.
    • Oral valganciclovir achieved high bioavailability, with 900 mg providing ganciclovir exposure similar to 5 mg/kg intravenous administration.
    • The tolerability profiles were similar during induction therapy.
    • Common adverse events during maintenance included neutropenia, anemia, and gastrointestinal issues.

    Conclusions:

    • Oral valganciclovir is an effective and well-tolerated alternative to intravenous ganciclovir for CMV retinitis in AIDS patients.
    • The high oral bioavailability of valganciclovir simplifies treatment regimens.
    • Valganciclovir offers a convenient oral option for managing CMV retinitis, potentially improving patient adherence and quality of life.